These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38384143)

  • 1. Nucleocapsid and Spike Protein-Based Anti-SARS-CoV-2 Assay Performance in the Minority and Rural Coronavirus Insights Study: Characteristics of Socioeconomically Disadvantaged Populations with Health Disparities.
    Christenson RH; Hansel S; II'yasova D; Meyer WA; Puckrein G; Lee L; Landry LG; Akinboboye O
    J Appl Lab Med; 2024 May; 9(3):493-501. PubMed ID: 38384143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
    Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
    Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.
    Mahmoud SA; Ganesan S; Naik S; Bissar S; Zamel IA; Warren KN; Zaher WA; Khan G
    Microbiol Spectr; 2021 Oct; 9(2):e0073321. PubMed ID: 34585943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
    Lumley SF; O'Donnell D; Stoesser NE; Matthews PC; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Jeffery K; Eyre DW;
    N Engl J Med; 2021 Feb; 384(6):533-540. PubMed ID: 33369366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2.
    Ouoba S; Sugiyama A; Ko K; Mirzaev UK; Abe K; E B; Phyo Z; Khalilov KK; Kurisu A; Akita T; Takahashi K; Sasaki H; Yamamoto T; Tanaka J
    J Med Virol; 2024 Aug; 96(8):e29826. PubMed ID: 39056254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
    Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
    Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
    Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
    Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence.
    Miller CN; Althoff KN; Schlueter DJ; Anton-Culver H; Chen Q; Garbett S; Ratsimbazafy F; Thomsen I; Karlson EW; Cicek M; Pinto LA; Malin BA; Ohno-Machado L; Williams C; Goldstein D; Kouame A; Ramirez A; Gebo KA; Schully SD;
    mSphere; 2022 Oct; 7(5):e0025722. PubMed ID: 36173112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline.
    Bolotin S; Tran V; Osman S; Brown KA; Buchan SA; Joh E; Deeks SL; Allen VG
    J Infect Dis; 2021 Apr; 223(8):1334-1338. PubMed ID: 33400794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
    Cameron A; Porterfield CA; Byron LD; Wang J; Pearson Z; Bohrhunter JL; Cardillo AB; Ryan-Muntz L; Sorensen RA; Caserta MT; Angeloni S; Hardy DJ; Zand MS; Pecora ND
    J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests.
    De Marco Verissimo C; O'Brien C; López Corrales J; Dorey A; Cwiklinski K; Lalor R; Doyle JM; Field S; Masterson C; Ribes Martinez E; Hughes G; Bergin C; Walshe K; McNicholas B; Laffey JG; Dalton JP; Kerr C; Doyle S
    Epidemiol Infect; 2021 Jun; 149():e140. PubMed ID: 34099081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of SARS-CoV-2 nucleocapsid and spike antibody detection using three commercially available automated immunoassays.
    Poore B; Nerenz RD; Brodis D; Brown CI; Cervinski MA; Hubbard JA
    Clin Biochem; 2021 Sep; 95():77-80. PubMed ID: 34118242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population.
    Wehrhahn MC; Brown SJ; Newcombe JP; Chong S; Evans J; Figtree M; Hainke L; Hueston L; Khan S; Marland E; O'Sullivan MVN; Powell H; Roy J; Waring L; Yu M; Robson J
    J Clin Virol; 2021 May; 138():104797. PubMed ID: 33770657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
    Guarino C; Larson E; Babasyan S; Rollins A; Joshi LR; Laverack M; Parrilla L; Plocharczyk E; Diel DG; Wagner B
    PLoS One; 2022; 17(1):e0262868. PubMed ID: 35061843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic.
    Edlow AG; Li JZ; Collier AY; Atyeo C; James KE; Boatin AA; Gray KJ; Bordt EA; Shook LL; Yonker LM; Fasano A; Diouf K; Croul N; Devane S; Yockey LJ; Lima R; Shui J; Matute JD; Lerou PH; Akinwunmi BO; Schmidt A; Feldman J; Hauser BM; Caradonna TM; De la Flor D; D'Avino P; Regan J; Corry H; Coxen K; Fajnzylber J; Pepin D; Seaman MS; Barouch DH; Walker BD; Yu XG; Kaimal AJ; Roberts DJ; Alter G
    JAMA Netw Open; 2020 Dec; 3(12):e2030455. PubMed ID: 33351086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins.
    Favresse J; Cadrobbi J; Eucher C; Elsen M; Laffineur K; Dogné JM; Douxfils J
    J Med Virol; 2021 Apr; 93(4):2262-2269. PubMed ID: 33200836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan.
    Nagura-Ikeda M; Imai K; Kubota K; Noguchi S; Kitagawa Y; Matsuoka M; Tabata S; Miyoshi K; Ito T; Tamura K; Maeda T
    J Med Microbiol; 2021 Apr; 70(4):. PubMed ID: 33861191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.